This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novartis purchases SB's Famvir and Vectavir/Denavir
In a deal worth $1.63bn, pharmaceutical conglomerate Novartis will acquire SmithKline Beecham's antiviral products Famvir (famciclovir) and Vectavir/Denavir (penciclovir). SB is divesting its antiviral line due to antitrust concerns in conjunction with its merger with Glaxo Wellcome.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?